{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:33:00Z","timestamp":1767652380579,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102027","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T02:36:56Z","timestamp":1582943816000},"page":"102027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5175-9541","authenticated-orcid":false,"given":"Marcus","family":"D'Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-1008","authenticated-orcid":false,"given":"Athina","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander U.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2020.102027_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102027_bib0002","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of nmo spectrum disorder and MOG-Encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.msard.2020.102027_bib0003","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2020.102027_bib0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102027_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.msard.2020.102027_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","article-title":"Investigational drugs in development to prevent neuromyelitis optica relapses","volume":"27","author":"Paul","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.msard.2020.102027_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102027_bib0008","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.msard.2020.102027_bib0009","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1212\/NXI.0000000000000269","article-title":"Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder","volume":"3","author":"Kessler","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"7","key":"10.1016\/j.msard.2020.102027_bib0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica-Ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2020.102027_bib0011","unstructured":"Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). Avalable at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02073279. (2019)."},{"key":"10.1016\/j.msard.2020.102027_bib0012","unstructured":"Neurostatus-EDSS Definitions 2011. Available at: https:\/\/www.neurostatus.net. (2019)."},{"key":"10.1016\/j.msard.2020.102027_bib0013","unstructured":"https:\/\/www.google.com\/forms\/about\/. (2019)."},{"year":"2008","series-title":"R: A language and Environment For Statistical Computing","key":"10.1016\/j.msard.2020.102027_bib0014"},{"issue":"6","key":"10.1016\/j.msard.2020.102027_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2020.102027_bib0016","unstructured":"Neurostatus.net [Internet]. Kappos L. neurostatus scoring definitions (Version 04\/10.2), 2011. [cited2018 Dec 26]. Available from: https:\/\/www.neurostatus.net\/."},{"issue":"5","key":"10.1016\/j.msard.2020.102027_bib0018","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:38Z","timestamp":1761900638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820301036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":17,"alternative-id":["S2211034820301036"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102027","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102027"}}